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Primary graft failure is a eatastrophic event in lung transplantation. 
Failure is characterized byprofound abnormalities ofgas exchange that are 
frequently unresponsive to alterations in mechanical ventilation. This 
condition can be fatal and, if less severe, is usually associated with 
significant permanent damage to the allograft. We report the use of 
extracorporeal membrane oxygenation as a means to support lung trans- 
plant recipients with severe graft failure. Since 1991, extracorporeal 
membrane oxygenation has been used on 17 occasions for the temporary 
support of 16 adult lung transplant recipients. All patients met or exceeded 
standard National Institutes of Health guidelines for institution of extra- 
corporeal membrane oxygenation. Nine double lung, six single lung, and 
one heart-lung recipients were supported for 1 to 12 days (mean 4.6 - 2.2 
days). Extracorporeal membrane oxygenation was instituted early, within 7 
days of transplantation, i  ten patients. Eight early patients (80%) were 
successfully weaned from extracorporeal membrane oxygenation. Seven of 
ten (70%) patients were long-term survivors, and five of the seven had 
normal ung function. In comparison, there were no survivors among six 
recipients placed on extracorporeal membrane oxygenation for late (>7 
days) graft dysfunction. Extracorporeal membrane oxygenation is a lifesav- 
ing adjunct in recipients with acute graft failure after lung transplantation. 
Ischemia-reperfusion njury and acute graft dysfunction after lung trans- 
plantation can be successfully reversed with early aggressive intervention. 
(J THORAC CARDIOVASC SURG 1995;110:723-7) 
Lawrence R. Glassman, MD, Robert J. Keenan, MD, 
M. Charlene Fabrizio, RNCCP, Josh R. Sonett, MD, Morris I. Bierman, MD, 
Si M. Pham, MD, and Bartley P. Griffith, MD, Pittsburgh, Pa. 
E xtracorporeal membrane oxygenation (ECMO) has been used in the pediatric population with 
great succes,;. Owing to the pioneering efforts of 
Bartlett and Gazzaniga 1 and Custer, 2 success rates 
of 90% and greater have been achieved. Outcome of 
adult patients with adult respiratory distress syn- 
drome supported with ECMO has been less favor- 
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able, with survival rates of 9% to 45%. 3-5 This 
retrospective report documents the use of ECMO 
for the support of 16 adult lung transplant recipients 
from 1991 to 1993. We believe that the success rate 
in this group of patients hould encourage the early 
use of ECMO, when necessary, in adult lung trans- 
plant recipients. 
Despite refined preservation techniques and im- 
proved early allograft survival, occasional lung 
transplant recipients have postimplantation graft 
dysfunction.6, 7 Primary graft failure, the inability of 
a pulmonary allograft to sustain ventilation and 
oxygenation despite full mechanical support, is po- 
tentially catastrophic. By offering full pulmonary 
and in some cases cardiopulmonary support, ECMO 
provides a means to stabilize the condition of the 
lung transplant recipient with profound graft dys- 
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Table I. Indications for ECMO 
Early (<7 days) Late (»-7 days) 
Fio2 >90 10/10 7/7 
Static compliance 3-25 (14) 6.5-16 (12.5) 
(ml/cm H20) 
Shunt fraction (%) 30-80 (40) 25-67 (41) 
Inotropic support 10/10 7/7 
Values in parentheses are mean values. 
function. This stabilization may allow time for al- 
lograft recovery or provide a window during which a 
second graft may be obtained. 
Pulmonary failure late after transplantation is 
offen multifactorial. Reversibility is dependent on 
the nature of the underlying pathologic ondition 
and the extent of the disease. Treatment of the late 
lung transplant dysfunction group includes early 
biopsy coupled with aggressive treatment of rejec- 
tion, infection, and other causative factors. When 
standard therapy with mechanical ventilation falls, 
ECMO may be added to the resuscitation algorithm. 
Patients and methods 
From February 1991 to December 1993 ECMO was 
required on 17 occasions to support 16 lung transplant 
recipients with profound graft failure. These 16 patients 
represent 7.4% of the 215 total patients who underwent 
transplantation between February 1991 and December 
1993. Nine double lung, six single lung, and one heart-lung 
recipients were supported for 1 to 12 days (mean 4.6 -+ 2.2 
days). Five patients underwent transplantation forchronic 
obstructive pulmonary disease, four for pulmonary hyper- 
tension, two for cystic fibrosis, two for bronchiectasis, two 
for pulmonary fibrosis, and one for lymphangiomyomato- 
sis. Graft preservation was accomplished with the combi- 
nation of prostaglandin Ex bolus into the donor pulmo- 
nary artery followed by hypothermic flush with a modified 
University of Wisconsin solution (80 to 100 ml/kg). Infu- 
sion rates were maintained with the use of a transportable 
roller pump. Donor lungs were stored in hypothermic 
preservation solution until implantation. Inflation with 
100% oxygen was maintained uring the interval from 
harvest o implantation. Mean ischemic times for the 
transplanted organs were 293 minutes (range 198 to 392 
minutes) for single or first lung and 394 minutes (range 
335 to 543 minutes) for the second lung. Double lung 
transplantations were pefformed with a bilateral single 
lung technique. Cardiopulmonary b pass was used in 
seven of the primary transplant proeedures. Four patients 
in this series underwent retransplantation. 
For the purposes of subgroup analysis, we have defined 
early graft dysfunction as that occurring within the first 7 
days of allograft implantation. Any patient placed on 
ECMO 1 week or longer after transplantation has been 
plaeed in the late dysfunction group. 
ECMO methodology. When criteria for ECMO were 
met, a Medtronic Carmeda heparin-bonded system 
(Medtronic Cardiopulmonary, Anaheim, Calif.) was used, 
and initial oxygenation was provided by two parallel 
Medtronic Maxima hollow-fiber oxygenators. A Bio- 
Medicus BP-80 centrifugal pump and flow probe 
(Medtronic Bio-Medicus, Eden Prairie, Minn.) with 3/8 
inch internal diameter × 3/32 inch wall thickness heparin- 
bonded tubing was used. Heparin was administered in the 
absence of bleeding to maintain acelite activated clotting 
time of more than 180 seconds (Hemochron activated 
clotting time sensor, International Technidyne Corpora- 
tion, Edison, N.J.). Oxygenators were changed only if 
foaming occurred. If it was necessary to change oxygen- 
ators and in the absence of bleeding, Maxima oxygenators 
(Medtronic) were changed to Avecor silicone rubber 
membrane systems (No. 3500 Avecor Cardiovascular Inc., 
Plymouth, Minn.). Heparinization to activated clotting 
time of more than 200 seconds was achieved. Initial 
priming was with Plasma-Lyte A solution (Baxter Health- 
care Corp., Deerfield, Ill.), which was then displaced with 
3 U of bank blood washed with a Cell Saver device 
(Haemonetics Corp., Braintree, Mass.), 75 mEq sodium 
bicarbonate, and 500 mg of calcium chloride. Total prim- 
ing volume was 1800 to 2200 rel. A dual Bird blender 
(Bird Products Corp., Palm Springs, Calif.) was used to 
achieve one inspired oxygen fraction (Fio2) setting. Con- 
tinuous blood gas monitoring was used routinely in the 
presence of continuous heparin therapy. Cannulation was 
performed at the surgeon's discretion by percutaneous or 
open methods. Carmeda coated cannulas were preferred. 
Choice of venovenous orvenoarterial support was based 
on hemodynamic stability. Venoarterial support was used 
at the surgeon's discretion for the more profoundly com- 
promised patients. 
Results 
We used ECMO on 17 occasions for the tempo- 
rary support of 16 adult lung transplant recipients. 
All patients met or exceeded standard National 
Institutes of Health guidelines for institution of 
ECMO. ECMO was initiated only when all standard 
cardiac and respiratory support maneuvers had 
failed. At the time of ECMO initiation, the arterial 
oxygen tension/Fio2 ratio (mean, 58.3 + 10, range 32 
to 81) was severely depressed. The average alveolar- 
arterial gradient was widened at 650 mm Hg. As 
expressed in Table I, ECMO was initiated only when 
Fio 2 requirements were severely elevated (->95%). 
Decreased static compliance (-<14 ml/cm H20 ) was 
indicative of severely elevated peak airway pressures 
despite ventilation with low tidal volumes. Shunt 
fraction was elevated in all patients (--40%). Al- 
though not part of standard National Institutes of 
Health guidelines, all patients at the time of institu- 
tion of ECMO also required the use of significant 
inotropic support. Despite the critieal pulmonary 
and hemodynamic state, overall patient survival was 
7 of 16 (48%). 
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Eight of ten early patients (Table Il) (80%) were 
weaned from ECMO, and seven of ten (70%) were 
long-term survivors. One of these patients was main- 
tained on ECMO for 3 days as a successful bridge to 
transplantation. One early patient was weaned from 
ECMO, unde, rwent retransplantation, and later died 
after a second period of ECMO support. Five of the 
seven patients had normal long-term lung function. 
One patient had an ischemic airway injury after 
ECMO; this injury was possibly related to venoar- 
terial perfusion in the absence of an intact bronchial 
circulation. 
In contrast o the 70% survivorship of the early 
group, only two of seven late patients were able to 
be weaned from ECMO for a brief interval, and 
none survived hospitalization. 
Complications in the 16 patients included epi- 
sodes of bleeding in four patients, one patient with 
ischemic airway injury, one patient with renal fail- 
ure, and one episode of cardiac tamponade requir- 
ing drainage. 
Discussion 
Givcn the critical pulmonary and hemodynamic 
state of these patients, we believe ECMO was a 
lifesaving adjunet. Initiation of ECMO was re- 
strieted to patients unable to be supported by con- 
ventional means. Application to the subgroup of 
patients within the first week of transplantation 
appeared to be most beneficial, with long-term 
survival of 70%. Potential ¢auses of aeute graft 
dysfunction in this early group include ischemia- 
reperfusion injury, prolonged preservation time, 
bleeding with multiple transfusions, cardiopulmo- 
nary bypass, circulatory arrest, significant active 
infection in the native pulmonary bed with release of 
septic mediators, te¢hnical eomplications, and un- 
derlying donor graft disease. We identified no tech- 
nical complications with graft harvest or preserva- 
tion in these patients. There does appear to be a 
reversible :component of pulmonary injury whieh 
may allow: for organ recovery during a period of 
ECMO support. Continued ventilation with high 
levels of oxygen and elevated airway pressures does 
not promote a climate of healing in an already 
damaged pulmonary bed. 
Eight of thirteen patients with venoarterial sup- 
port and two of four patients with venovenous 
support were long-term survivors. Because of the 
small number of patients, we are unable to draw a 
conclusion as to which form of perfusion is more 
successful. Our preference is to use venovenous 
Table II. ECMO patient characteristics 
Early Late 
(<7 days) (>-7 days) 
Mean age (yr) 43 42 
Interval Tx to ECMO 0-6 (1.9) 8-390 (77) 
(days) 
Duration ECMO (days) 1-9 (4) 1-11 (4) 
Weaned from ECMO 8/10 2/7 
Discharged ffom hospital 7/10 0/7 
Retransplantation 2 2 
Survive retransplantation 1 0 
VV ECMO 2 2 
VA ECMO 8 5 
Values in parentheses are mean values. Tx, Transplantation; VV, veno- 
venous; VA, venoarterial. 
bypass for those patients who have hemodynami- 
cally stable conditions. Venoarterial perfusion is 
chosen for those patients with profound hemody- 
namic instability or readily accessible central arterial 
circulation. 
Graft dysfunction may be a critical problem after 
lung transplantation. Although conservative therapy 
may suffice, further support may be necessary to 
allow patients to survivefi In a report by the Wash- 
ington University group, 9 donor lung dysfunction 
occurred in 20% of patients. One of seven patients 
with early graft dysfunction required retransplanta- 
tion, and a second was successfully supported for 3 
days with ECMO. 
In this group of 17 patients, ECMO was more 
likely to be successful within the first week after 
transplantation (70% survival) than later (0% sur- 
vival) after surgery. If the diagnosis of severe post- 
transplantation lung injury has been established, it 
appears that ECMO support is potentially lifesav- 
ing. Although impossible to prove, early institution 
of ECMO may alleviate the potential long-term 
consequences of oxygen toxicity and barotrauma on 
a newly implanted allograft. ECMO support permits 
a period of ventilation at lower airway pressures and 
a decrease in Fio2, both of which may be beneficial 
during this critical phase. 
The failure of ECMO support o potentiate sur- 
vival in the late dysfunction group underscores the 
difficulty of rescuing patients with severe pneumo- 
nitis or allograft rejection unresponsive to standard 
medical therapy. 
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Discuss ion 
Dr. Robert M. Kass (Los An$eles, Caliß). The use of 
ECMO as adjunctive therapy for respiratory failure in 
adult patients has a checkered history. A recent review 
earlier this year in the American Journal of Respiratory and 
Critical Care Medicine of a randomized clinical trial of 
ECMO concluded that survival of patients with adult 
respiratory distress syndrome (ARDS) was not signifi- 
cantly different regardless of whether ECMO was used 
instead of more traditional therapeutic modalities. The 
survival in each group was significantly less than 50%. 
In the group of patients presented to us here, of those 
patients placed on ECMO within 7 days of transplanta- 
tion, seven of ten were long-term survivors and, signifi- 
cantly, five of seven had normal lung function. These 
results lead to my first question: What do the authors 
believe is significantly different about the lung transplant 
recipieut versus the group of patients with ARDS that 
results in improved survival characteristics? Also, a sec- 
ond related question: In what ways did the patients placed 
on ECMO more than 7 days after transplantation differ 
from those placed on ECMO earlier? 
Dr. Glassman. In regard to the first question, the 
difference in these patients versus patients with ARDS, I 
believe that these lungs are generally sound when we 
harvest and implant hem, and we are looking at a severe 
form of a reperfusion injury perhaps in association with 
the use of cardiopulmonary b pass and multiple transfu- 
sions which accompanied a large number of these cases of 
early graft failure. These are clearly reversible after 
support of the patients with ECMO as opposed to support 
of patients with ARDS where the origin may be a more 
long-standing insult to the lung. 
The second question was related to the early and late 
groups. I think the answer is similar; the late groups have 
either well established infection or well established bad 
rejection and pneumonitis that is not easily reversible 
versus an accumulation of perhaps increased pulmonary 
water with the early group. The support on ECMO allows 
time for that to come out of the pulmonary bed. 
Dr. Kass. The Washington University Lung Transplant 
Group in St. Louis reported a clinical experience treat- 
ing seven patients with primary graft dysfunction after 
lung transplantation i  the conventional manner without 
ECMO. Their overall survival was 100%, with one of the 
patients requiring retransplantation. How are the authors 
able to reconcile their use of ECMO when the apparent 
survival of patients reported by Washington University 
with primary graft dysfunction is excellent with more 
traditional therapy? 
Dr. Glassman. We have had a number of patients who 
were not included in this group that I think would fall into 
the group that was reported from the Washington Uni- 
versity group. I think that there are clearly a number of 
levels of acute graft dysfunction that orte can see after 
lung transplantation a d this is in my mind very much the 
end-stage spectrum of acute graft dysfunction. I am 
convinced that, with all these patients not only requiring 
90% to 100% oxygen but also having high peak airway 
pressure, poor compliance, and inotropic support, we 
would not have had a survival rate of 70% in this group 
without ECMO. Now, it certainly is not a randomized 
series and I do not believe ethically it would be reasonable 
to withhold ECMO if you believed that it was an impor- 
tant adjunct for the therapy of these patients, which I 
believe it is. 
Dr. Walter Dembitsky (San Diego, Calif.). We have 
been interested in ECMO support for critically ill patients 
for some time, and we have begun to relearn some of the 
lessons of the early ECMO trial. One of them is that 
prolonged venoarterial bypass can produce stasis throm- 
bosis both in the lungs and in the native ventricle. The 
question is this: In these two groups that you had, 
venoarterial versus veno-venous ECMO, were there dif- 
ferences in times of support? 
Dr. Glassman. No, there were no differences in times of 
venoarterial and venovenous upport. They were the 
same, and I think the point you made about thrombosis 
an important one. In the absence of bleeding, we antico- 
agulated the patients to aetivated clotting times of greater 
than 180 seconds early on, and in the article I have 
detailed that we actually anticoagulated them to activated 
clotting times of 200 to 300 seconds after 48 hours of 
ECMO support. In the absence of bleeding we believed as 
well that anticoagulation was important. 
Dr. Dembitsky. I think that stasis thrombosis can occur 
eren with pretty fair degrees of anticoagulation, and so I 
think with the trend in the country being to support 
patients who are critically ill with peripheral bypass in the 
venoarterial mode, we are going to be seeing more and 
more problems related to thrombosis. 
Dr. Paul Waters (Los Angeles, Calif.). Could you share 
with us a little about he indications for transplantation in 
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the group of patients you reported? Was there a predom- 
inance of one diagnosis versus another? Was there any- 
thing in the preoperative assessment that led you subse- 
quently to notice why they would end up being supported 
with ECMO and having graft failure? 
Dr. Glassman. They were a fairly broad-based group 
of patients. They included orte patient with lymphangio- 
leiomyomatosis, about four patients with chronic ob- 
structive pulmonary disease, and several patients with 
pulmonary hypertension. In the group who underwent 
transplantation early, seven of ten patients had cardio- 
pulmonary bypass, indicating that either they had sig- 
nificant pulmonary hypertension--one of the patients 
was a patient with a patent ductus arteriosus who 
underwent repair with circulatory arrest - -or  other pre- 
operative factors which would have required cardiopul- 
monary bypass. There is a report in the last Journal of 
Heart and Lung Transplantation from the Pittsburgh 
group looking at the incidence of early graft dysfunction 
with the use of cardiopulmonary b pass and it seems to 
be somewhat higher. Therefore, I would say that those 
patients who have increased incidence of cardiopulmo- 
nary bypass for lung transplantation may be at higher 
risk. 
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